PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRifampin
Rifampin
Rifadin, Rifamate, Rifampin, Rifater, Rimactane (rifampin) is a small molecule pharmaceutical. Rifampin was first approved as Rifamate on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, bacterial meningitis, brucellosis, and haemophilus infections amongst others in the USA. It is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 1B1, solute carrier organic anion transporter family member 1B3, and nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Rifadin, Rifampin, Rimactane (discontinued: Rifadin, Rifampin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifampin
Tradename
Company
Number
Date
Products
RIMACTANEOxford PharmaceuticalsN-050429 RX1982-01-01
1 products
RIFADINSanofiN-050627 RX1989-05-25
1 products, RLD, RS
Show 1 discontinued
Isoniazid
+
Pyrazinamide
+
Rifampin
Tradename
Company
Number
Date
Products
RIFATERSanofiN-050705 DISCN1994-05-31
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
mycobutinNew Drug Application2024-12-24
priftinNew Drug Application2024-07-12
rifabutinNDA authorized generic2025-05-22
rifadin2007-07-16
rifadin ivNew Drug Application2025-05-14
rifadin iv novaplusNew Drug Application2025-05-14
rifadin rifadin ivNew Drug Application2021-12-01
rifadin rifadin iv novaplusNew Drug Application2017-05-04
rifampinANDA2025-04-02
taliciaNew Drug Application2024-05-01
Show 1 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
tuberculosisEFO_0000774D014376A15-A19
bacterial infections—D001424A49
legionnaires' diseaseEFO_0007343D007877A48.1
staphylococcal infections—D013203A49.01
bacterial meningitisEFO_1000831D016920G00
brucellosisEFO_0007185D002006A23
aids-related opportunistic infections—D017088—
leprosyEFO_0001054D007918A30
haemophilus infectionsEFO_1001127D006192—
mycobacterium infections—D009164A31.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AB: Antibiotics, antitubercular
— J04AB02: Rifampicin
— J04AM: Combinations of drugs for treatment of tuberculosis
— J04AM02: Rifampicin and isoniazid
— J04AM05: Rifampicin, pyrazinamide and isoniazid
— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid
— J04AM07: Rifampicin, ethambutol and isoniazid
— J04B: Drugs for treatment of lepra
— J04BA: Drugs for treatment of lepra
— J04BA50: Dapsone and rifampicin
— J04BA51: Dapsone, rifampicin and clofazimine
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameRifampin
INNrifampicin
Description
Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires' disease. It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. Rifampicin may be given either by mouth or intravenously.
Classification
Small molecule
Drug classtricyclic compounds; antibiotics (rifamycin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Identifiers
PDB—
CAS-ID13292-46-1
RxCUI—
ChEMBL IDCHEMBL374478
ChEBI ID28077
PubChem CID5381226
DrugBankDB01045
UNII IDVJT6J7R4TR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLCO1A2
SLCO1A2
SLCO1B1
SLCO1B1
SLCO1B3
SLCO1B3
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
SLCO1A2
Gene synonyms
OATP, OATP1, OATP1A2, SLC21A3
NCBI Gene ID
6579
Protein name
solute carrier organic anion transporter family member 1A2
Protein synonyms
OATP-1, OATP-A, organic anion transporting polypeptide A, Organic anion-transporting polypeptide 1, Sodium-independent organic anion transporter, solute carrier family 21 (organic anion transporter), member 3, Solute carrier family 21 member 3
Uniprot ID
Q9UGP7
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Rifampin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use